|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 | |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H1 2018 ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on ... Iduronate 2 Sulfatase - Pipeline Review, H1 2020 ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on ... Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on ... Enzyme Replacement Therapy Market Size, Trends, Analysis, and Outlook By Product (Agalsidase Beta, Imiglucerase , Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others), By Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), By End-User (Hospitals, Infusion Centers & Home Healthcare Setting), by Region, Country, Segment, and Companies, 2024-2030 ... (Agalsidase Beta, Imiglucerase , Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others), By Disease (Gaucher ... Agalsidase Beta Imiglucerase Velaglucerase Alfa Idursulfase Galsulfase Laronidase Others By Disease Gaucher ... Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), by End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029 ... : Agalsidase Beta Imiglucerase Velaglucerase Alfa Idursulfase Galsulfase Laronidase Others By Disease: Gaucher ... Lysosomal Storage Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type [Enzyme Replacement Therapy {Velaglucerase Alfa, Alglucosidase Alfa (Myozyme/Lumizyme), Idursulfase (Elaprase), Imiglucerase (Cerezyme), Others}; Substrate Reduction Therapy, Others], By Disease Type [Gaucher Disease, Mucopolysaccharidoses, Pompe Disease, Fabry Disease, Others], By Region and Competition, 2020-2030F ... 6.24 million per year in some contexts. Idursulfase (Elaprase) for Hunter syndrome has ... Genzyme Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... intellectual property relating to Aldurazyme. Elaprase (idursulfase): Elaprase is an enzyme replacement therapy developed ... Iduronate 2 Sulfatase - Drugs In Development, 2021 ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on ... Iduronate 2 Sulfatase - Pipeline Review, H2 2020 ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on ... Global Iduronate 2 Sulfatase Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close ... , covers Alpha L Iduronate Sulfate Sulfatase Idursulfase IDS EC 3.1.6.13 Market Segment by Applications, can ... Global Iduronate 2 Sulfatase Market 2024 by Company, Regions, Type and Application, Forecast to 2030 ... (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target ... Alpha L Iduronate Sulfate Sulfatase, Idursulfase), Ambulatory Surgical Centers (Alpha ... Alpha L Iduronate Sulfate Sulfatase Idursulfase IDS EC 3.1.6.13 Market segment ... Global Iduronate 2 Sulfatase Market Growth (Status and Outlook) 2024-2030 ... Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target ... L Iduronate Sulfate Sulfatase, Idursulfase), and regional breakdowns. ... Alpha L Iduronate Sulfate Sulfatase Idursulfase IDS EC 3.1.6.13 Segmentation by application ... Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Enzyme Replacement Therapy, Substrate Reduction Therapy), By Disease Type, By Region, And Segment Forecasts, 2025 - 2033 ... Alfa Alglucosidase Alfa (Myozyme/Lumizyme) Idursulfase (Elaprase) Imiglucerase (Cerezyme) Others Substrate ... U.S. Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy (ERT)), By Disease Type, By Country, And Segment Forecasts, 2025 - 2033 ... (Cerezyme) Alglucosidase alfa (Myozyme/Lumizyme) Idursulfase (Elaprase) Velaglucerase alfa Others Substrate ... Iduronate 2 Sulfatase Market - Global Outlook and Forecast 2022-2028 ... 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close ... , 2021 (%) Alpha L Iduronate Sulfate Sulfatase Idursulfase IDS EC 3.1.6.13 Global Iduronate 2 Sulfatase Market ... Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2020 Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2020 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2020, provides an overview of the ... Mucopolysaccharidosis II - Pipeline Review, H1 2017 Mucopolysaccharidosis II - Pipeline Review, H1 2017 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2017, provides an overview of the Mucopolysaccharidosis II ( ... Enzyme Replacement Therapy (ERT) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application ... and HTA endorsements for idursulfase in MPS II, where national funds ... at 25% share, deploys sulfatases like idursulfase for heparan sulfate clearance, yielding ... propels ADZYNMA (apadamtase alfa), ELAPRASE (idursulfase), Replagal (agalsidase alfa), and ... Hunter Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 ... adoption of enzyme replacement therapy with idursulfase, that aims to replace the deficient ... Mucopolysaccharidoses Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 ... replacement therapies (ERTs) like laronidase, idursulfase, elosulfase alfa, etc., which help ... |